Summary of study ST000196

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000178. The data can be accessed directly via it's Project DOI: 10.21228/M8VS3Q This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  |  Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data (Contains raw data)
Study IDST000196
Study TitleMurine gastrointestinal bile acid profiles before and after antibiotics
Study TypeBile acid analysis (colon contents/plasma)
Study SummaryClostridium difficile infection (CDI) following antibiotic therapy is a major public health threat. While antibiotic disruption of the indigenous microbiota underlies the majority of cases of CDI, the early dynamics of infection in the disturbed intestinal ecosystem are poorly characterized. This study defines the dynamics of infection with C. difficile strain VPI 10463 throughout the gastrointestinal (GI) tract using a murine model of infection. After inducing susceptibility to C. difficile colonization via antibiotic administration, we followed the dynamics of spore germination, colonization, sporulation, toxin activity, and disease progression throughout the GI tract. C. difficile spores were able to germinate within 6 h postchallenge, resulting in the establishment of vegetative bacteria in the distal GI tract. Spores and cytotoxin activity were detected by 24 h postchallenge, and histopathologic colitis developed by 30 h. Within 36 h, all infected mice succumbed to infection. We correlated the establishment of infection with changes in the microbiota and bile acid profile of the small and large intestines. Antibiotic administration resulted in significant changes to the microbiota in the small and large intestines, as well as a significant shift in the abundance of primary and secondary bile acids. Ex vivo analysis suggested the small intestine as the site of spore germination. This study provides an integrated understanding of the timing and location of the events surrounding C. difficile colonization and identifies potential targets for the development of new therapeutic strategies. Research is published: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4333439/
Institute
University of Michigan
DepartmentBiomedical Research Core Facilities
LaboratoryMetabolomics core
Last NameKachman
First NameMaureen
Address6300 Brehm Tower, 1000 Wall Street, Ann Arbor, MI 48105-5714
Email mkachman@umich.edu
Submit Date2015-06-09
Num Groups26
Total Subjects135
Raw Data AvailableYes
Raw Data File Type(s).xml,.xsd,.stg, .bin, .cd,.cG
Uploaded File Size256 M
Analysis Type DetailLC-MS
Release Date2015-12-28
Release Version1
Maureen Kachman Maureen Kachman
https://dx.doi.org/10.21228/M8VS3Q
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:


Project:

Project ID:PR000178
Project DOI:doi: 10.21228/M8VS3Q
Project Title:Bile Acid Studies in Murine Gut
Project Summary:Targeted bile acid analysis throughout the murine GI tract before and after antibiotics
Institute:University of Michigan
Department:Int Med-Infectious Diseases
Laboratory:Theriot Lab
Last Name:Theriot
First Name:Casey
Address:Ann Arbor, MI
Email:caseythe@umich.edu
Phone:734-763-4133

Subject:

Subject ID:SU000215
Subject Type:Animal
Subject Species:Mus musculus
Taxonomy ID:10090
Species Group:Mammal

Factors:

Subject type: Animal; Subject species: Mus musculus (Factor headings shown in green)

mb_sample_id local_sample_id Recovery Gender Treatment
SA009836S00015979five week recovery female Cefoperazone treated
SA009837S00015978five week recovery female Cefoperazone treated
SA009838S00016046five week recovery female Cefoperazone treated
SA009839S00016048five week recovery male Cefoperazone treated
SA009840S00016047five week recovery male Cefoperazone treated
SA009841S00015981five week recovery male Cefoperazone treated
SA009842S00015980five week recovery male Cefoperazone treated
SA009843S00015975four week recovery female Cefoperazone treated
SA009844S00016044four week recovery female Cefoperazone treated
SA009845S00015974four week recovery female Cefoperazone treated
SA009846S00016043four week recovery female Cefoperazone treated
SA009847S00016045four week recovery male Cefoperazone treated
SA009848S00015977four week recovery male Cefoperazone treated
SA009849S00015976four week recovery male Cefoperazone treated
SA009850S00016081na female No antibiotics
SA009851S00016015na female No antibiotics
SA009852S00016083na female No antibiotics
SA009853S00016013na female No antibiotics
SA009854S00016082na female No antibiotics
SA009855S00016014na female No antibiotics
SA009856S00016086na male No antibiotics
SA009857S00016085na male No antibiotics
SA009858S00016016na male No antibiotics
SA009859S00016084na male No antibiotics
SA009860S00016018na male No antibiotics
SA009861S00016017na male No antibiotics
SA009862S00016020no recovery female Cefoperazone treated
SA009863S00016021no recovery female Cefoperazone treated
SA009864S00015952no recovery female Cefoperazone treated
SA009865S00016019no recovery female Cefoperazone treated
SA009866S00015953no recovery female Cefoperazone treated
SA009867S00016053no recovery female IP clindamycin
SA009868S00016054no recovery female IP clindamycin
SA009869S00015986no recovery female IP clindamycin
SA009870S00015987no recovery female IP clindamycin
SA009871S00016052no recovery female IP clindamycin
SA009872S00016078no recovery female Kanamycin treated
SA009873S00016012no recovery female Kanamycin treated
SA009874S00016080no recovery female Kanamycin treated
SA009875S00016010no recovery female Kanamycin treated
SA009876S00016079no recovery female Kanamycin treated
SA009877S00016011no recovery female Kanamycin treated
SA009878S00016007no recovery female Metronidazole treated
SA009879S00016075no recovery female Metronidazole treated
SA009880S00016073no recovery female Metronidazole treated
SA009881S00016006no recovery female Metronidazole treated
SA009882S00016074no recovery female Metronidazole treated
SA009883S00016069no recovery female Vancomycin treated
SA009884S00016002no recovery female Vancomycin treated
SA009885S00016000no recovery female Vancomycin treated
SA009886S00016001no recovery female Vancomycin treated
SA009887S00016068no recovery female Vancomycin treated
SA009888S00016067no recovery female Vancomycin treated
SA009889S00015954no recovery male Cefoperazone treated
SA009890S00015955no recovery male Cefoperazone treated
SA009891S00016023no recovery male Cefoperazone treated
SA009892S00016022no recovery male Cefoperazone treated
SA009893S00016024no recovery male Cefoperazone treated
SA009894S00016056no recovery male IP clindamycin
SA009895S00015988no recovery male IP clindamycin
SA009896S00015989no recovery male IP clindamycin
SA009897S00016057no recovery male IP clindamycin
SA009898S00015990no recovery male IP clindamycin
SA009899S00016055no recovery male IP clindamycin
SA009900S00016008no recovery male Kanamycin treated
SA009901S00016009no recovery male Kanamycin treated
SA009902S00016076no recovery male Kanamycin treated
SA009903S00016077no recovery male Kanamycin treated
SA009904S00016003no recovery male Metronidazole treated
SA009905S00016072no recovery male Metronidazole treated
SA009906S00016004no recovery male Metronidazole treated
SA009907S00016005no recovery male Metronidazole treated
SA009908S00016071no recovery male Metronidazole treated
SA009909S00016070no recovery male Metronidazole treated
SA009910S00015997no recovery male Vancomycin treated
SA009911S00016066no recovery male Vancomycin treated
SA009912S00015998no recovery male Vancomycin treated
SA009913S00015999no recovery male Vancomycin treated
SA009914S00016064no recovery male Vancomycin treated
SA009915S00016065no recovery male Vancomycin treated
SA009916S00015957one week recovery female Cefoperazone treated
SA009917S00016025one week recovery female Cefoperazone treated
SA009918S00015956one week recovery female Cefoperazone treated
SA009919S00015958one week recovery female Cefoperazone treated
SA009920S00015959one week recovery female Cefoperazone treated
SA009921S00016026one week recovery female Cefoperazone treated
SA009922S00016027one week recovery female Cefoperazone treated
SA009923S00015960one week recovery male Cefoperazone treated
SA009924S00015961one week recovery male Cefoperazone treated
SA009925S00016028one week recovery male Cefoperazone treated
SA009926S00016029one week recovery male Cefoperazone treated
SA009927S00016030one week recovery male Cefoperazone treated
SA009928S00015983six week recovery female Cefoperazone treated
SA009929S00016050six week recovery female Cefoperazone treated
SA009930S00016049six week recovery female Cefoperazone treated
SA009931S00015982six week recovery female Cefoperazone treated
SA009932S00016059six week recovery female Cefoperazone treated IP clindamycin
SA009933S00016060six week recovery female Cefoperazone treated IP clindamycin
SA009934S00015991six week recovery female Cefoperazone treated IP clindamycin
SA009935S00015992six week recovery female Cefoperazone treated IP clindamycin
Showing page 1 of 2     Results:    1  2  Next     Showing results 1 to 100 of 135

Collection:

Collection ID:CO000203
Sample Type:Cecum

Treatment:

Treatment ID:TR000223

Sample Preparation:

Sampleprep ID:SP000217
Sampleprep Protocol Filename:Bile-acids-2015-03-11.docx

Combined analysis:

Analysis ID AN000298
Analysis type MS
Chromatography type Reversed phase
Chromatography system
Column Waters Acquity BEH C18 (50 x 2.1mm, 1.7um)
MS Type ESI
MS instrument type Triple quadrupole
MS instrument name Agilent 6490 QQQ
Ion Mode NEGATIVE
Units µg/100mg sample weight

Chromatography:

Chromatography ID:CH000219
Methods ID:AQM041
Methods Filename:2014-07-30-Bile_acid-full-BEH-C18-h.m.zip
Column Name:Waters Acquity BEH C18 (50 x 2.1mm, 1.7um)
Chromatography Type:Reversed phase

MS:

MS ID:MS000247
Analysis ID:AN000298
Instrument Name:Agilent 6490 QQQ
Instrument Type:Triple quadrupole
MS Type:ESI
Ion Mode:NEGATIVE
  logo